Journal
THERANOSTICS
Volume 6, Issue 9, Pages 1324-1335Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.14882
Keywords
Nano-theranostics; Hsp90 inhibitor; Photo-therapy; Combination therapy; Prostate cancer
Categories
Funding
- NIH/NCI [3R01CA115483, R01CA199668]
- NIH/NIBIB [R01EB012569]
- DoD PRMRP Award [W81XWH-13-1-0490]
- NIH/NICHD [1R01HD086195]
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD086195] Funding Source: NIH RePORTER
- NATIONAL CANCER INSTITUTE [R01CA115483, R01CA199668] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB012569] Funding Source: NIH RePORTER
- Veterans Affairs [I01BX001784] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Photodynamic therapy (PDT) is a promising non-invasive therapeutic modality that has been proposed for treating prostate cancer, but the procedure is associated with limited efficacy, tumor recurrence and photo-toxicity. In the present study, we proposed to develop a novel multifunctional nano-platform for targeted delivery of heat, reactive oxygen species (ROS) and heat shock protein 90 (Hsp90) inhibitor simultaneously for combination therapy against prostate cancer. This new nano-platform combines two newly developed entities: 1) a unique organic and biocompatible nanoporphyrin-based drug delivery system that can generate efficient heat and ROS simultaneously with light activation at the tumor sites for dual-modal photothermal-and photodynamic-therapy (PTT/PDT), and 2) new nano-formulations of Hsp90 inhibitors that can decrease the levels of pro-survival and angiogenic signaling molecules induced by phototherapy, therefore, further sensitizing cancer cells to phototherapy. Furthermore, the nanoparticles have activatable near infrared (NIR) fluorescence for optical imaging to conveniently monitor the real-time drug delivery in both subcutaneous and orthotopic mouse models bearing prostate cancer xenograft. This novel multifunctional nano-platform has great potential to improve the care of prostate cancer patients through targeted combination therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available